These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20077513)

  • 21. Balanced two-stage designs for phase II clinical trials.
    Ye F; Shyr Y
    Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methods for one-sided testing of the difference between proportions and sample size considerations related to non-inferiority clinical trials.
    Dann RS; Koch GG
    Pharm Stat; 2008; 7(2):130-41. PubMed ID: 17526060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
    Leon AC
    J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increasing the sample size at interim for a two-sample experiment without Type I error inflation.
    Dunnigan K; King DW
    Pharm Stat; 2010; 9(4):280-7. PubMed ID: 19764040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sample size allocation to regions in a multiregional trial.
    Uesaka H
    J Biopharm Stat; 2009 Jul; 19(4):580-94. PubMed ID: 20183427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating the adaptive performance of flexible sample size designs with treatment difference in an interval.
    Liu GF; Zhu GR; Cui L
    Stat Med; 2008 Feb; 27(4):584-96. PubMed ID: 17634972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis.
    Friede T; Kieser M
    Pharm Stat; 2011; 10(1):8-13. PubMed ID: 19943322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomization by minimization for unbalanced treatment allocation.
    Han B; Enas NH; McEntegart D
    Stat Med; 2009 Nov; 28(27):3329-46. PubMed ID: 19739238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimization of sample size when comparing two small probabilities in a non-inferiority safety trial.
    de Boo TM; Zielhuis GA
    Stat Med; 2004 Jun; 23(11):1683-99. PubMed ID: 15160402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal spending functions for asymmetric group sequential designs.
    Anderson KM
    Biom J; 2007 Jun; 49(3):337-45. PubMed ID: 17623339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Test equality and sample size calculation based on risk difference in a randomized clinical trial with noncompliance and missing outcomes.
    Lui KJ; Chang KC
    Biom J; 2008 Apr; 50(2):224-36. PubMed ID: 18264992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sample size estimation for the van Elteren test--a stratified Wilcoxon-Mann-Whitney test.
    Zhao YD
    Stat Med; 2006 Aug; 25(15):2675-87. PubMed ID: 16372389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statistical efficiency in multiple-to-one comparison trials with optimal allocation ratio.
    Zhang J; Zhang JJ
    J Biopharm Stat; 2011 Jan; 21(1):125-35. PubMed ID: 21191859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sample sizes for clinical trials with time-to-event endpoints and competing risks.
    Schulgen G; Olschewski M; Krane V; Wanner C; Ruf G; Schumacher M
    Contemp Clin Trials; 2005 Jun; 26(3):386-96. PubMed ID: 15911472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of adaptive allocation rules for group-sequential binary response clinical trials.
    Morgan CC; Stephen Coad D
    Stat Med; 2007 Apr; 26(9):1937-54. PubMed ID: 16981177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A SAS macro for sample size adjustment and randomization test for internal pilot study.
    Wang S; Xia J; Yu L; Li C; Xu L
    Comput Methods Programs Biomed; 2008 Apr; 90(1):66-88. PubMed ID: 18192069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A note on P-values under group sequential testing and nonproportional hazards.
    Gillen DL; Emerson SS
    Biometrics; 2005 Jun; 61(2):546-51. PubMed ID: 16011703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sample size estimation for non-inferiority trials of time-to-event data.
    Crisp A; Curtis P
    Pharm Stat; 2008; 7(4):236-44. PubMed ID: 17583558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.